Other featured articles

• Young People Treated in Pediatric Emergency Departments Less Likely to Receive Opioids Compared to Similar Patients Treated in General EDs

  Since the 1990s, children, adolescents, and young adults have also experienced dramatic increases in exposure to and harms from prescription opioids.

  Posted in

  Articles > Press Releases
• Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs

  Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best pricing metric to use for them?

  By Alice Chen, PhD and Dana Goldman, PhD

  Posted in

  Perspectives > Pharmaceutical Pricing and Medical Innovation
• State Drug Pricing Transparency Laws: Numerous Efforts, Most Fall Short

  166 recently enacted prescription drug pricing laws were analyzed to identify those that contained price transparency measures. Of these, 35 bills in 22 states include a transparency component, but only 7 were deemed to be informative.

  Posted in

  White Papers > Pharmaceutical Pricing and Medical Innovation
• Losing Summer: 10 Months. Nearly 30 Visits to San Francisco’s Psychiatric ER. And a Suicide

  Summer’s story reveals the weaknesses in San Francisco’s mental illness and addiction treatment system.

  Posted in

  Articles